A cheap, naturally occurring metabolite mixed into the chow of middle-aged mice made the females live longer and stay healthier. That is the headline from a 2020 Cell Metabolism paper on calcium alpha-ketoglutarate (CaAKG), and it has been recycled across the supplement internet ever since. The result is real and interesting. It is also a mouse result, and this paper does not establish that CaAKG extends human lifespan or healthspan.
The Study in Brief
The research, led by Azar Asadi Shahmirzadi and colleagues, tested CaAKG in C57BL/6 mice across two independent cohorts, with roughly 182 animals in total and about 45 females and 45 males per cohort. The animals were not young. The 2% (w/w) CaAKG diet began at around 540 days of age, roughly middle age for this strain. The team tracked lifespan and ran longitudinal, clinically oriented healthspan measurements, including frailty assessment.
Starting treatment in middle age matters. Many longevity claims rest on interventions begun early in life. Showing an effect after midlife is more translationally interesting, though it still tells us nothing definitive about people.
Why Alpha-Ketoglutarate? The TCA Cycle Rationale
Alpha-ketoglutarate (AKG) is an intermediate in the tricarboxylic acid (TCA, or Krebs) cycle, the core metabolic pathway that helps cells turn nutrients into usable energy. It is endogenous, meaning the body makes it. The authors note that its levels shift with fasting, exercise, and aging, which makes it a plausible link between metabolism and the aging process.
That rationale is a hypothesis, not proof of benefit in humans. A metabolite changing with age does not mean that supplementing it reverses age-related decline. Even in this mouse paper, the mechanism is framed as a proposal.
The form also matters from a delivery standpoint. The researchers used a calcium salt, CaAKG, in the diet rather than free AKG. How well different salt forms are absorbed, distributed, and used in tissues is a separate question that this paper does not resolve for human use.
The Numbers: Females Clearly Benefited, Males Less Clearly
The lifespan data are where the details count, and they are less uniform than the "up to 16.6%" headline suggests.
Females:
- Cohort 1: median lifespan extended by 16.6% and 90th-percentile survival by 19.7%, measured from the start of treatment.
- Cohort 2: median lifespan extended by 10.5% and survival by 8%.
So "up to ~16.6%" is the best case from one cohort, and the replication cohort showed a smaller effect. Both are statistically meaningful improvements in female mice, but the range is the honest summary, not the peak.
Males: median lifespan was numerically longer, roughly 9.6–12.8%, but the survival improvement was not statistically significant. The male data are therefore suggestive at best, and the paper's clearest lifespan signal is in females. Sex differences are a recurring theme in aging research, and they are one more reason not to generalize a single mouse strain's results to people.
Compression of Morbidity: Less Frailty, Not Just More Time
Living longer is only half the claim. The authors also report reduced frailty, and they describe the combination as a compression of morbidity: the period of poor health at the end of life is squeezed rather than stretched. That is the outcome longevity researchers want, because extending lifespan without extending healthspan simply prolongs decline.
Again, this was observed in mice using mouse-appropriate frailty measures. It supports the idea that AKG might affect healthspan in the animal model. It does not show that humans taking AKG supplements would be less frail or live longer.
The Inflammation and IL-10 Angle
The proposed mechanism centers on chronic inflammation. CaAKG-fed mice showed lower levels of systemic inflammatory cytokines, and the authors propose that dietary AKG induces IL-10, an anti-inflammatory cytokine, which in turn suppresses chronic inflammation and yields health benefits.
This fits a broader view of aging in which persistent low-grade inflammation, often called "inflammaging," contributes to age-related decline. But the IL-10 explanation is the authors' proposal, not a fully proven causal chain, and it comes from mice. Whether oral AKG would shift inflammatory signaling in older humans in a comparable or beneficial way is an open question.
What Marketers Say vs. What the Paper Shows
| Common marketing claim | What this paper actually supports |
|---|---|
| "Proven to extend lifespan" | Extended median lifespan in female C57BL/6 mice; male survival gains were not significant. No human lifespan data. |
| "Reverses aging" | The paper reports reduced frailty and compressed morbidity in mice, not reversal of aging in any species. |
| "Clinically shown in humans" | Not from this study. It is an animal study with no human randomized trial. |
| "Optimal dose is 2%" | 2% of the diet by weight in mice. This is not a validated human dose. |
| "Works for everyone" | Effects differed by sex, and the study used one mouse strain. |
The gap between the paper and the marketing is wide. Mouse lifespan studies are valuable hypothesis generators, but they have a long history of failing to translate to people. Dose scaling, differences in metabolism, diet, lifespan length, and disease patterns all complicate extrapolation.
Limitations Worth Repeating
- Mouse-only evidence. This study cannot establish human longevity benefits.
- Dose uncertainty. A 2% dietary concentration in mice does not translate into a known safe or effective human supplement dose.
- Sex-specific effects. Females showed clear survival gains; males did not reach significance for survival.
- Cohort variability. The female benefit shrank from 16.6% to 10.5% (median) between cohorts.
- Mechanism not settled. IL-10 induction is proposed, not definitively demonstrated as the cause.
Practical Takeaway: A Research Watchlist, Not a Protocol
For readers following longevity science, CaAKG belongs on the watchlist. It is a biologically plausible, endogenous metabolite with a notable middle-age-onset lifespan signal in female mice and a compelling healthspan narrative. The next steps that would matter are replication in other mouse strains and labs, clearer pharmacokinetic and delivery data, and, crucially, well-designed human trials with meaningful endpoints.
Until then, this paper is not a basis for a human anti-aging protocol. Anyone considering AKG or any supplement, especially people with medical conditions or who take medications, should talk with a clinician. The honest summary is this: CaAKG extended lifespan and reduced frailty in aging mice, most convincingly in females, and human longevity benefits remain unproven.
